A decision on whether to approve Pfizer's COVID pill for the European Union could come within weeks, the EU's drug regulator announced Monday, following a formal application for authorization from the U.S. pharma giant.
In December the European Medicines Agency (EMA) cleared individual states to decide whether to make early emergency use of the drug known as Paxlovid.
But the Amsterdam-based watchdog said it had now started evaluating Pfizer's bid for full authorization across the 27-nation bloc.
"EMA will assess the benefits and risks of Paxlovid under a reduced timeline and could issue an opinion within weeks," the agency said in a statement.
The timing depended on whether Pfizer's data was "sufficiently robust," it added.
The watchdog is weighing a similar application for a pill from Pfizer's U.S. rival Merck.
The U.S. authorized both the Pfizer and Merck pills in December.
The two drugs have been hailed as potentially groundbreaking in the fight against COVID-19 as studies show they cut the risk of hospitalization and death in high-risk patients.
Being pills, they are also more accessible than treatments that have to be given by injection or intravenously.
The Pfizer pill is a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir, that are taken as separate tablets.
